India, June 10 -- Rafael Holdings, Inc. (RFL), a clinical and early-stage biopharmaceutical company, announced that its last patient has completed their final 96-week study visit in the pivotal Phase 3 trial, TransportNPC, which evaluated Trappsol Cyclo for the treatment of Niemann-Pick disease type C (NPC).
Company Profile
Rafael Holdings is focused on the development and commercialization of therapies for oncology and rare diseases. The company through its subsidiary Cyclo Therapeutics advances a portfolio of preclinical and clinical candidates to address unmet medical needs.
Niemann-Pick Disease Type C (NPC)
It is a rare, fatal, and progressive genetic disorder caused by a defect in the NPC1 protein. This condition is characterized b...